Cornea

Examining the physiologic limits can help identify when its usage may be ineffective

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

A retrospective study from a UK tertiary centre reports satisfactory visual and topographic outcomes in patients monitored and treated by optometrists and nurse practitioners.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Two years after LASIK, hidden corneal nerve loss and immune activation persist, with higher IL‑16 and faster T‑cell motion despite normal exams.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

NYU researchers discuss using CellChek C widefield specular microscopy to visualize and quantify corneal nerves in dry eye disease, revealing reduced nerve fiber length and inferior whorl changes and offering a practical alternative to in vivo confocal imaging.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

Madhura Tamhankar, MD, took some time at the ARVO conference in Denver, Colorado, to discuss a poster on disease progression in thyroid eye disease, stressing what we know about the Rundle Curve may not be accurate.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

Understanding thyroid eye disease and its often-missed diagnosis.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

The trial is evaluating AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction

Engineered ocular bacteria act as a long-lasting eye drop, secreting IL-10 to speed corneal healing and hint at future living therapies.

The phase 3 study was a randomized, double-masked, placebo-controlled, multicenter trial evaluating subcutaneous teprotumumab administered every 2 weeks for 24 weeks.

Immunovant, along with partner HanAll, will assess future plans for the development of batoclimab and provide an update at a future, unspecified date

Five-year pediatric Boston KPro results show vision gains, but low retention and high membrane, melt and glaucoma risks persist.

Phase 3 shows epi-on oxygen CXL flattens pediatric keratoconus, improves vision, and stays well tolerated—now commercially available.

An off-the-shelf corneal cell injection targets FECD and bullous keratopathy, aiming to restore vision and ease donor shortages.

QoL areas measured included enjoying relationships/life, overall mood, and time spent thinking of eye pain.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.